Reports Q4 revenue C$77.984M vs C$83.153M last year. “Since taking over as CEO in January, we took decisive actions to accelerate growth and profitability by unifying our medical cannabis businesses globally, aligning operations with commercial focus, increasing rigor on core fundamentals and streamlining our product portfolio. With renewed focus and our resources dedicated to the most promising opportunities, I’m confident that our leading brands and product innovation pipeline can deliver meaningful growth and long-term value for both consumers and shareholders.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGC:
- Options Volatility and Implied Earnings Moves Today, May 30, 2025
- CGC Upcoming Earnings Report: What to Expect?
- Options Volatility and Implied Earnings Moves This Week, May 27 – May 30, 2025
- CGC Lawsuit Alert! Class Action Lawsuit Against Canopy Growth Corporation
- Canopy Growth to Announce Q4 and Fiscal Year 2025 Financial Results